Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117018) titled 'To study the clinical efficacy and safety of tolecizumab at different dosing intervals in the treatment of patients with hyperlipidemia' on Jan. 19.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial
Condition:
Hyperlipidemia
Intervention:
Group A(Q2W):None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-31
Target Sample Size: Group A(Q2W):30;Group B(Q3W):30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj...